The most recent Market Talks masking the Well being Care sector. Revealed solely on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
0747 ET – Novo Nordisk’s shares appear to be overreacting to the information that the important thing ingredient in its Ozempic and Wegovy blockbuster medication failed to point out a profit in Alzheimer’s illness in medical trials, analysts at J.P. Morgan say in a analysis word. Whereas this implies a possible constructive shock didn’t materialize, it has no impression on forecasts for the Danish drugmaker, the analysts say. “We and nearly all of the market had seen this trial as excessive threat and because of this we had included zero contribution from Alzheimer’s illness in our forecasts,” the analysts say. Consensus expectations embody a minor contribution of seven billion Danish kroner ($1.08 billion) in 2032 gross sales, or about 2% of the group’s whole, in keeping with JPM. Shares fall 10%, dropping to ranges final seen in 2021. (adria.calatayud@wsj.com)
Copyright ©2025 Dow Jones & Firm, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
